Shilpa Medicare has received approval from CDSCO, New Delhi for manufacturing and sale of Lenvatinib Capsules, 12, 18 and 24 mg in India. Shilpa will commercialize the product under the brand name Lenshil. Lenshil 12 mg and Lenshil 18 mg will be launched immediately followed by Lenshil 24 mg.

Shilpa Medicare is the first company to receive approval for Lenvatinib Capsules, 12, 18 and 24 mg in India. The company is already marketing the 4 mg and 10 mg strengths. The first time launch of this new drug in India will offer great benefits in terms of flexibility of dosage and patient convenience in specific cancer indications. For treating hepatocellular carcinoma, the recommended dosage is 12 mg orally once daily for patients greater than or equal to 60 kg. For treating Renal Cell Carcinoma (RCC) the recommended dosage is 18 mg orally once daily and for Differentiated Thyroid Cancer the recommended daily dose of Lenvatinib is 24 mg once daily.

Shilpa's first-in-India - Lenshil 12 mg, Lenshil 18 mg and Lenshil 24 mg will allow physicians and patients to administer only one capsule instead of three capsules of the currently available 4 mg and 10 mg strengths. Lenshil is a bioequivalent and pharmaceutically equivalent version of the brand product Lenvima of Eisai, USA.

Shilpa Medicare Limited, is a research driven, global, integrated pharmaceutical company, headquartered in Raichur, Karnataka, India and is engaged in research and development, manufacturing and sale of oncology drugs and formulations.